Literature DB >> 12768179

Cardiovascular and pulmonary effects of epidural anaesthesia.

B Th Veering1.   

Abstract

The cardiovascular effects observed with epidural anaesthesia are complex and are predominantly related to the extent of sympathetic denervation, autonomous balance, baseline blood volume and cardiovascular function of the patient. With epidural anaesthesia the pharmacological effect of systemically absorbed local anaesthetic agents and inclusion of adrenaline to the local anaesthetic solution may play a role. Individual cardiovascular response to different levels of sympathetic blockade varies widely, depending on the degree of sympathetic tone prior to the block. Epidural anaesthesia per se has little effect on respiration in patients with pre-existing lung disease. Thoracic epidural anaesthesia appears to reverse the diaphragmatic dysfunction which is a major determinant of the decrease in lung volumes observed after upper abdominal surgery. This article summarizes cardiovascular and pulmonary responses to epidural anaesthesia.

Entities:  

Mesh:

Year:  2003        PMID: 12768179

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  3 in total

Review 1.  [Concepts for perioperative pain therapy. A critical stocktaking].

Authors:  S Reichl; E Pogatzki-Zahn
Journal:  Anaesthesist       Date:  2009-09       Impact factor: 1.041

2.  Role of epidural ketamine for postoperative analgesia after upper abdominal surgery.

Authors:  Mamta Sethi; Nitin Sethi; Pradeep Jain; Jayashree Sood
Journal:  Indian J Anaesth       Date:  2011-03

3.  Cardiovascular and respiratory effects of lumbosacral epidural bupivacaine in isoflurane-anesthetized dogs: The effects of two volumes of 0.25% solution.

Authors:  Raquel Sartori Gonçalves Dias; João Henrique Neves Soares; Douglas Dos Santos E Castro; Maria Alice Kuster de Albuquerque Gress; Marcela Lemos Machado; Pablo E Otero; Fabio Otero Ascoli
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.